Accelus announced that more than 15,000 FlareHawk® multiplanar expandable cages have been implanted in more than 11,000 patients in the United States.
The FlareHawk portfolio of expandable lumbar fusion devices includes FlareHawk9, FlareHawk7 and the titanium-coated TiHawk7, TiHawk9 and TiHawk11 cages. FlareHawk cages all feature Accelus’s innovative Adaptive Geometry™, which allows the devices to be inserted with a minimal insertion profile before expanding in width, height and lordosis. This controlled, in situ multiplanar expansion is designed to restore foraminal height, reestablish sagittal balance and help reduce implant subsidence.
FlareHawk received FDA 510(k) clearance in August 2016 and CE mark certification in April 2021. It is currently approved in 19 countries worldwide.
“I’m incredibly proud to have hit this milestone with FlareHawk, and the fact that it is supported by an evidence-based, multicenter, peer-reviewed, published study demonstrating 97% fusion,” said Chris Walsh, Co-Founder and Chief Executive Officer of Accelus.
Accelus announced that more than 15,000 FlareHawk® multiplanar expandable cages have been implanted in more than 11,000 patients in the United States.
The FlareHawk portfolio of expandable lumbar fusion devices includes FlareHawk9, FlareHawk7 and the titanium-coated TiHawk7, TiHawk9 and TiHawk11 cages. FlareHawk cages all feature Accelus’s...
Accelus announced that more than 15,000 FlareHawk® multiplanar expandable cages have been implanted in more than 11,000 patients in the United States.
The FlareHawk portfolio of expandable lumbar fusion devices includes FlareHawk9, FlareHawk7 and the titanium-coated TiHawk7, TiHawk9 and TiHawk11 cages. FlareHawk cages all feature Accelus’s innovative Adaptive Geometry™, which allows the devices to be inserted with a minimal insertion profile before expanding in width, height and lordosis. This controlled, in situ multiplanar expansion is designed to restore foraminal height, reestablish sagittal balance and help reduce implant subsidence.
FlareHawk received FDA 510(k) clearance in August 2016 and CE mark certification in April 2021. It is currently approved in 19 countries worldwide.
“I’m incredibly proud to have hit this milestone with FlareHawk, and the fact that it is supported by an evidence-based, multicenter, peer-reviewed, published study demonstrating 97% fusion,” said Chris Walsh, Co-Founder and Chief Executive Officer of Accelus.
Copy to clipboard 
